134 related articles for article (PubMed ID: 24366498)
1. Protocadherin-17 promoter methylation in serum-derived DNA is associated with poor prognosis of bladder cancer.
Luo ZG; Li ZG; Gui SL; Chi BJ; Ma JG
J Int Med Res; 2014 Feb; 42(1):35-41. PubMed ID: 24366498
[TBL] [Abstract][Full Text] [Related]
2. Protocadherin 17 promoter methylation in tumour tissue from patients with bladder transitional cell carcinoma.
Wang XB; Lin YL; Li ZG; Ma JH; Li J; Ma JG
J Int Med Res; 2014 Apr; 42(2):292-9. PubMed ID: 24567353
[TBL] [Abstract][Full Text] [Related]
3. Clinical and prognostic significance of protocadherin-10 (PCDH10) promoter methylation in bladder cancer.
Lin YL; Li ZG; He ZK; Guan TY; Ma JG
J Int Med Res; 2012; 40(6):2117-23. PubMed ID: 23321168
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of protocadherin-8 (PCDH8) promoter methylation in bladder cancer.
Lin YL; Ma JH; Luo XL; Guan TY; Li ZG
J Int Med Res; 2013 Feb; 41(1):48-54. PubMed ID: 23569129
[TBL] [Abstract][Full Text] [Related]
5. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection.
Hoque MO; Begum S; Topaloglu O; Chatterjee A; Rosenbaum E; Van Criekinge W; Westra WH; Schoenberg M; Zahurak M; Goodman SN; Sidransky D
J Natl Cancer Inst; 2006 Jul; 98(14):996-1004. PubMed ID: 16849682
[TBL] [Abstract][Full Text] [Related]
6. The clinical significance of PCDH10 promoter methylation in patients with bladder transitional cell carcinoma.
Lin YL; Li ZG; Guan TY
Urol Int; 2013; 90(2):219-24. PubMed ID: 23171734
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of protocadherin 8 (PCDH8) promoter methylation in non-muscle invasive bladder cancer.
Lin YL; Wang YL; Ma JG; Li WP
J Exp Clin Cancer Res; 2014 Aug; 33(1):68. PubMed ID: 25927589
[TBL] [Abstract][Full Text] [Related]
8. Protocadherin17 Promoter Methylation is a Potential Predictive Biomarker in Clear Cell Renal Cell Carcinoma.
Lin YL; Gui SL; Guo H; Ma JG; Li WP
Med Sci Monit; 2015 Sep; 21():2870-6. PubMed ID: 26404644
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of CDH13 promoter methylation in serum samples from patients with bladder transitional cell carcinoma.
Lin YL; Sun G; Liu XQ; Li WP; Ma JG
J Int Med Res; 2011; 39(1):179-86. PubMed ID: 21672320
[TBL] [Abstract][Full Text] [Related]
10. RUNX3 methylation as a predictor for disease progression in patients with non-muscle-invasive bladder cancer.
Yan C; Kim YW; Ha YS; Kim IY; Kim YJ; Yun SJ; Moon SK; Bae SC; Kim WJ
J Surg Oncol; 2012 Mar; 105(4):425-30. PubMed ID: 22311819
[TBL] [Abstract][Full Text] [Related]
11. Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer.
Kim JS; Chae Y; Ha YS; Kim IY; Byun SS; Yun SJ; Kim WJ
Clin Genitourin Cancer; 2012 Jun; 10(2):114-20. PubMed ID: 22382007
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of the methylated cytosine-phosphate-guanine sites of protocadherin-10 promoter for evaluating the prognosis of gastric cancer.
Deng J; Liang H; Ying G; Dong Q; Zhang L; Yu J; Fan D; Hao X
J Am Coll Surg; 2014 Nov; 219(5):904-13. PubMed ID: 25260683
[TBL] [Abstract][Full Text] [Related]
13. Aberrant Promoter Methylation of PCDH17 (Protocadherin 17) in Serum and its Clinical Significance in Renal Cell Carcinoma.
Lin YL; Wang YP; Li HZ; Zhang X
Med Sci Monit; 2017 Jul; 23():3318-3323. PubMed ID: 28688232
[TBL] [Abstract][Full Text] [Related]
14. Accurate detection of upper tract urothelial carcinoma in tissue and urine by means of quantitative GDF15, TMEFF2 and VIM promoter methylation.
Monteiro-Reis S; Leça L; Almeida M; Antunes L; Monteiro P; Dias PC; Morais A; Oliveira J; Henrique R; Jerónimo C
Eur J Cancer; 2014 Jan; 50(1):226-33. PubMed ID: 24100025
[TBL] [Abstract][Full Text] [Related]
15. Aberrant methylation of protocadherin 17 and its prognostic value in pediatric acute lymphoblastic leukemia.
Uyen TN; Sakashita K; Al-Kzayer LF; Nakazawa Y; Kurata T; Koike K
Pediatr Blood Cancer; 2017 Mar; 64(3):. PubMed ID: 27643535
[TBL] [Abstract][Full Text] [Related]
16. Aberrant methylation of protocadherin 17 and its clinical significance in patients with prostate cancer after radical prostatectomy.
Lin YL; Xie PG; Wang L; Ma JG
Med Sci Monit; 2014 Aug; 20():1376-82. PubMed ID: 25091018
[TBL] [Abstract][Full Text] [Related]
17. Recurrent transcriptional loss of the PCDH17 tumor suppressor in laryngeal squamous cell carcinoma is partially mediated by aberrant promoter DNA methylation.
Byzia E; Soloch N; Bodnar M; Szaumkessel M; Kiwerska K; Kostrzewska-Poczekaj M; Jarmuz-Szymczak M; Szylberg L; Wierzbicka M; Bartochowska A; Kalinowicz E; Grenman R; Szyfter K; Marszalek A; Giefing M
Mol Carcinog; 2018 Jul; 57(7):878-885. PubMed ID: 29566279
[TBL] [Abstract][Full Text] [Related]
18. Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients.
Friedrich MG; Weisenberger DJ; Cheng JC; Chandrasoma S; Siegmund KD; Gonzalgo ML; Toma MI; Huland H; Yoo C; Tsai YC; Nichols PW; Bochner BH; Jones PA; Liang G
Clin Cancer Res; 2004 Nov; 10(22):7457-65. PubMed ID: 15569975
[TBL] [Abstract][Full Text] [Related]
19. Promoter hypermethylation identifies progression risk in bladder cancer.
Yates DR; Rehman I; Abbod MF; Meuth M; Cross SS; Linkens DA; Hamdy FC; Catto JW
Clin Cancer Res; 2007 Apr; 13(7):2046-53. PubMed ID: 17404085
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of opioid binding protein/cell adhesion molecule-like promoter methylation in bladder carcinoma.
Duarte-Pereira S; Paiva F; Costa VL; Ramalho-Carvalho J; Savva-Bordalo J; Rodrigues A; Ribeiro FR; Silva VM; Oliveira J; Henrique R; Jerónimo C
Eur J Cancer; 2011 May; 47(7):1106-14. PubMed ID: 21273058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]